Agenda - PDCO agenda of the 14-17 October 2025 meeting
Submitted by Anonymous (not verified) on 14 October 2025 - 9:04
Agenda - PDCO agenda of the 14-17 October 2025 meeting
Timetable: Type II variation and worksharing application monthly assessment
Submitted by Anonymous (not verified) on 14 October 2025 - 9:01
Timetable: Type II variation and worksharing application monthly assessment
Timetable: Type II variation and worksharing application alternative monthly assessment
Submitted by Anonymous (not verified) on 14 October 2025 - 9:01
Timetable: Type II variation and worksharing application alternative monthly assessment
Timetable: Post-authorisation measure (PAM) assessed by PRAC
Submitted by Anonymous (not verified) on 14 October 2025 - 9:00
Timetable: Post-authorisation measure (PAM) assessed by PRAC
Respiporc Flu3 : EPAR - Medicine overview
Submitted by Anonymous (not verified) on 14 October 2025 - 9:00
Respiporc Flu3 : EPAR - Medicine overview
List of clinical evaluation consultation procedure (CECP) opinions issued for medical devices awaiting finalisation of conformity assessment
Submitted by Anonymous (not verified) on 14 October 2025 - 7:58
List of clinical evaluation consultation procedure (CECP) opinions issued for medical devices awaiting finalisation of conformity assessment
Respiporc Flu3 : EPAR - All Authorised presentations
Submitted by Anonymous (not verified) on 14 October 2025 - 1:00
Respiporc Flu3 : EPAR - All Authorised presentations
Suvaxyn Circo+MH RTU : EPAR - Public assessment report
Submitted by Anonymous (not verified) on 14 October 2025 - 0:00
Suvaxyn Circo+MH RTU : EPAR - Public assessment report
Respiporc Flu3 : EPAR - Scientific Discussion
Submitted by Anonymous (not verified) on 14 October 2025 - 0:00
Respiporc Flu3 : EPAR - Scientific Discussion
Human medicines European public assessment report (EPAR): Ilaris, canakinumab, Date of authorisation: 23/10/2009, Revision: 34, Status: Authorised
Submitted by Anonymous (not verified) on 13 October 2025 - 16:45
Human medicines European public assessment report (EPAR): Ilaris, canakinumab, Date of authorisation: 23/10/2009, Revision: 34, Status: Authorised